BioGaia AB (publ) (BIOGY) Stock | BIOGY Stock Price & Analysis

Feed

BIOGY

BioGaia AB (publ) BIOGY OTC · Healthcare · Sweden

$12.45 +0.00% +$0.00

Summary

70 / 100 · Bulios Score

Valuation 11Growth 36Profitability 97Quality 99Debt 100Stability 83

What speaks for it

Out of every 100 SEK of revenue, 24 SEK is left as net profit.
It earns 31 SEK a year on every 100 SEK of invested capital.
It has no debt and holds 524.2M kr in cash.
Revenue grew by 12% a year over the last 3 years.

What to watch

Earnings per share fell by 3.8% a year over the last 3 years.
It pays out more in dividends than it earns: 110% of profit.
You pay 32.3 SEK for 1 SEK of yearly profit, a lot for its sector.

Bulios Scoring describes a company's quality and track record, not its future return. A high score is not a buy signal. Learn more

Score in detail

Is it expensive?

Fairly priced

Bulios Fair Price

Fair Value Price today $12.45

By our assumptions the price matches the value of the business: the two differ by less than 10 %.

P/E today 32.3 2.9% lower

5-year average P/E 33.2

P/E today 32.3

Drug Manufacturers - Specialty & Generic industry median

Unlock fair price

Bulios Fair Price is an estimate of a stock's fair value from the Bulios valuation model. It is an input for your own analysis, not investment advice. How does it work?

Today you pay 32.3 SEK for 1 SEK of yearly profit. Over the last five years it was 33.2 SEK on average.

Valuation in detail

Is it growing?

Slowly

Revenue (SEK)

785M

1.1B

1.3B

1.4B

1.5B

1.7B

1.9B

2021202220232024202520262027

Diluted EPS (SEK)

1.94 kr

3.70 kr

3.62 kr

3.48 kr

3.29 kr

20212022202320242025

Analyst estimate

Revenue grew by 16% a year over 5 years. Over the last 3 years it grew by 12% a year.

Growth in detail

Does it make money?

Very well

Where 100 SEK of revenue goes

Cost of sales 27 SEK
Research and development 5.5 SEK
Sales and administration 38 SEK
Taxes and other 5.8 SEK
Net profit 24 SEK

Net profit, industry median (Drug Manufacturers - Specialty & Generic) 9.9 SEK

Out of every 100 SEK of revenue, 24 SEK is left as net profit.

Profitability in detail

Is it financially healthy?

Yes

Cash and short-term investments 524.2M kr

Debt 0.00 kr

Free cash flow over 12 months 258.1M kr

It has no debt.

Financial health in detail

Does it pay a dividend?

Moderate, at risk

0.16

0.59

0.28

0.63

0.71

20212022202320242025

Yield: 3.40%
Paid out of profit: 110%
Raised in a row: 2 years

You receive $0.42 per share a year. The payout is more than the company can comfortably cover.

Dividends in detail

What do analysts expect?

No coverage

No analyst covers this stock.

Analysts in detail

What does it earn on?

By product

The company reports no revenue by product.

By region

The company reports no revenue by region.

Segments in detail